{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:08:29Z","timestamp":1726124909311},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T00:00:00Z","timestamp":1452297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11255-015-1195-6","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T08:19:55Z","timestamp":1452327595000},"page":"571-584","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"48","author":[{"given":"Panpan","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"issue":"5 Suppl 5","key":"1195_CR1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1053\/ajkd.2001.28113","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38(5 Suppl 5):S20\u2013S33","journal-title":"Am J Kidney Dis"},{"key":"1195_CR2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1074\/jbc.M207872200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, Kusano K, Kinosaki M et al (2003) Human fibroblast growth factor-23 mutants suppress Na1-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 278:2206\u20132211","journal-title":"J Biol Chem"},{"issue":"1","key":"1195_CR3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bj\u00f6rklund P, Marsell R et al (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. Endocrinology 195(1):125\u2013131","journal-title":"Endocrinology"},{"issue":"3","key":"1195_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Bone Miner Res 19(3):429\u2013435","journal-title":"Bone Miner Res"},{"key":"1195_CR5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","volume":"56","author":"M Rix","year":"1999","unstructured":"Rix M, Andreassen H, Eskildsen P et al (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084\u20131093","journal-title":"Kidney Int"},{"key":"1195_CR6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358\u20131366","journal-title":"Kidney Int"},{"key":"1195_CR7","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","volume":"16","author":"Y Slinin","year":"2005","unstructured":"Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788\u20131793","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519\u2013530","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1195_CR9","first-page":"S50","volume":"76","author":"National Kidney Foundation","year":"2009","unstructured":"National Kidney Foundation (2009) Chapter 4.1: treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 76(2):S50\u2013S99","journal-title":"Kidney Int"},{"key":"1195_CR10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/ndt\/gft227","volume":"28","author":"DW Coyne","year":"2013","unstructured":"Coyne DW, Andress DL, Amdahl MJ et al (2013) Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 28:2260\u20132268","journal-title":"Nephrol Dial Transplant"},{"key":"1195_CR11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","volume":"321","author":"DL Andress","year":"1989","unstructured":"Andress DL, Norris KC, Coburn JW et al (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274\u2013279","journal-title":"N Engl J Med"},{"issue":"4 Suppl 2","key":"1195_CR12","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/ajkd.1998.v32.pm9808142","volume":"32","author":"E Slatopolsky","year":"1998","unstructured":"Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32(4 Suppl 2):S40\u2013S47","journal-title":"Am J Kidney Dis"},{"key":"1195_CR13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"JL Finch","year":"1999","unstructured":"Finch JL, Brown AJ, Slatopolsky E (1999) Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980\u2013985","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P et al (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276","journal-title":"Am J Kidney Dis"},{"key":"1195_CR16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonzalez EA, Gellens M et al (1998) 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427\u20131432","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E et al (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446\u2013456","journal-title":"N Engl J Med"},{"key":"1195_CR18","first-page":"320560","volume":"2013","author":"T Han","year":"2013","unstructured":"Han T, Rong G, Quan D et al (2013) Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int 2013:320560","journal-title":"Biomed Res Int"},{"key":"1195_CR19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2215\/CJN.03000311","volume":"7","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang W, Zhang X et al (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391\u2013400","journal-title":"Clin J Am Soc Nephrol"},{"key":"1195_CR20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1440-1797.2008.01058.x","volume":"14","author":"AH Abdul Gafor","year":"2009","unstructured":"Abdul Gafor AH, Saidin R, Loo CY et al (2009) Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology 14:488\u2013492","journal-title":"Nephrology"},{"key":"1195_CR21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M et al (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483\u20131490","journal-title":"Kidney Int"},{"key":"1195_CR22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","volume":"18","author":"LM Ong","year":"2013","unstructured":"Ong LM, Narayanan P, Goh HK et al (2013) Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology 18:194\u2013200","journal-title":"Nephrology"},{"key":"1195_CR23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M et al (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD. Clin J Am Soc Nephrol 9:1620\u20131626","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1195_CR24","first-page":"CD008175","volume":"7","author":"SC Palmer","year":"2009","unstructured":"Palmer SC, McGregor DO, Craig JC et al (2009) Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 7(4):CD008175. doi: 10.1002\/14651858.CD008175","journal-title":"Cochrane Database Syst Rev"},{"key":"1195_CR25","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions version 5.0.0. The Cochrane Collaboration 2008: Editors. http:\/\/www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"1195_CR26","doi-asserted-by":"crossref","first-page":"e0118174","DOI":"10.1371\/journal.pone.0118174","volume":"10","author":"E Riccio","year":"2015","unstructured":"Riccio E, Sabbatini M, Bruzzese D et al (2015) Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS ONE 10:e0118174","journal-title":"PLoS ONE"},{"key":"1195_CR27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5301\/ijao.5000309","volume":"37","author":"D Yonova","year":"2014","unstructured":"Yonova D, Vazelov E, Tcakova A et al (2014) Paricalcitol therapy and the inflammatory markers in peritoneal dialysis patients. Int J Artif Organs 37:607","journal-title":"Int J Artif Organs"},{"issue":"5","key":"1195_CR28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.2013111185","volume":"26","author":"M Trillini","year":"2015","unstructured":"Trillini M, Cortinovis M, Ruggenenti P et al (2015) Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 26(5):1205\u20131214","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR29","first-page":"ii509","volume":"27","author":"S Sezer","year":"2012","unstructured":"Sezer S, Tutal E, Bal Z et al (2012) Treatment of secondary hyperparathyroidism in maintenance hemodialysis patients: a randomised clinical trial comparing paricalcitol, calcitriol and sinacalcet. Nephrol Dial Transplant 27:ii509\u2013ii510","journal-title":"Nephrol Dial Transplant"},{"key":"1195_CR30","first-page":"33","volume":"52","author":"AN Kharlamov","year":"2012","unstructured":"Kharlamov AN, Perrish AN, Gabiskii Ia L et al (2012) Vitamin D in the treatment of cardiorenal syndrome in patients with chronic nephropathy. Kardiologiia 52:33\u201344","journal-title":"Kardiologiia"},{"key":"1195_CR31","first-page":"894A","volume":"24","author":"SE Rosas","year":"2013","unstructured":"Rosas SE, Yang W, Litt H (2013) A phase IV, randomized, blinded single-center study of the effects of calcitriol and paricalcitol on vascular calcification in chronic kidney disease stages 3 and 4-vitamin D and coronary calcification study (VCOR). J Am Soc Nephrol 24:894A","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR32","first-page":"ii242","volume":"27","author":"M Nikodimopoulou","year":"2012","unstructured":"Nikodimopoulou M, Liakos S, Kapoulas S et al (2012) Alfacalcidol and paricalcitol have similar effects on left ventricular hypertrophy. Nephrol Dial Transplant 27:ii242","journal-title":"Nephrol Dial Transplant"},{"key":"1195_CR33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10157-013-0844-2","volume":"18","author":"EJ Jamaluddin","year":"2014","unstructured":"Jamaluddin EJ, Gafor AH, Yean LC et al (2014) Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 18:507\u2013514","journal-title":"Clin Exp Nephrol"},{"key":"1195_CR34","first-page":"B4400","volume":"59","author":"D Hansen","year":"2012","unstructured":"Hansen D (2012) A randomised clinical study of alfacalcidol and paricalcitol. Dan Med J 59:B4400","journal-title":"Dan Med J"},{"key":"1195_CR35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000266204","volume":"31","author":"RJ Lund","year":"2010","unstructured":"Lund RJ, Andress DL, Amdahl M et al (2010) Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 31:165\u2013170","journal-title":"Am J Nephrol"},{"issue":"5","key":"1195_CR36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"JL Finch","year":"1999","unstructured":"Finch JL, Brown AJ, Slatopolsky E et al (1999) Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10(5):980\u2013985","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2014.01.016","volume":"61","author":"E Streja","year":"2014","unstructured":"Streja E, Wang HY, Lau WL et al (2014) Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone 61:201\u2013207","journal-title":"Bone"},{"key":"1195_CR38","author":"N Mittman","year":"2010","unstructured":"Mittman N, Desiraju B, Meyer KB et al (2010) Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int. doi: 10.1038\/ki.2010.191","journal-title":"Kidney Int"},{"issue":"4","key":"1195_CR39","doi-asserted-by":"crossref","first-page":"E638","DOI":"10.1210\/jc.2012-4007","volume":"98","author":"AJ Ballegooijen van","year":"2013","unstructured":"van Ballegooijen AJ, Reinders I, Visser M et al (2013) Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 98(4):E638\u2013E645. doi: 10.1210\/jc.2012-4007","journal-title":"J Clin Endocrinol Metab"},{"key":"1195_CR40","author":"T Shoji","year":"2014","unstructured":"Shoji T, Marubayashi S, Shigematsu T et al (2014) Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. Ther Apher Dial. doi: 10.1111\/1744-9987","journal-title":"Ther Apher Dial"},{"key":"1195_CR41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3747\/pdi.2012.00324","volume":"35","author":"TC Bond","year":"2015","unstructured":"Bond TC, Wilson S, Moran J et al (2015) Mortality rates do not differ among patients prescribed various vitamin D agents. Perit Dial Int 35:62\u201369","journal-title":"Perit Dial Int"},{"issue":"1","key":"1195_CR42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2369-14-199","volume":"14","author":"Z Zheng","year":"2013","unstructured":"Zheng Z, Shi H, Jia J et al (2013) Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 14(1):199. doi: 10.1186\/1471-2369-14-199","journal-title":"BMC Nephrol"},{"key":"1195_CR43","author":"XH Li","year":"2015","unstructured":"Li XH, Feng L, Yang ZH et al (2015) The effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology. doi: 10.1111\/nep.12505","journal-title":"Nephrology"},{"issue":"7","key":"1195_CR44","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674\u2013684","journal-title":"JAMA"},{"issue":"1","key":"1195_CR45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J et al (2014) Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial. J Am Soc Nephrol 25(1):175\u2013186","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1195_CR46","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s11255-013-0637-2","volume":"46","author":"AL Negri","year":"2014","unstructured":"Negri AL, Brandenburg VM (2014) Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism. Int Urol Nephrol 46(6):1145\u20131151","journal-title":"Int Urol Nephrol"},{"key":"1195_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","volume":"34","author":"HZ Tonbul","year":"2012","unstructured":"Tonbul HZ, Solak Y, Atalay H et al (2012) Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail 34:297\u2013303","journal-title":"Ren Fail"},{"issue":"5 Suppl 5","key":"1195_CR48","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M et al (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(5 Suppl 5):S45\u2013S50","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1195_CR49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11255-009-9574-5","volume":"42","author":"T Ogawa","year":"2010","unstructured":"Ogawa T, Ishida H, Akamatsu M et al (2010) Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. Int Urol Nephrol 42(1):187\u2013194","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1195_CR50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-005-0385-4","volume":"9","author":"M Ketteler","year":"2005","unstructured":"Ketteler M, Westenfeld R, Schlieper G et al (2005) Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol 9(4):265\u2013270","journal-title":"Clin Exp Nephrol"},{"key":"1195_CR51","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2013.02.366","volume":"62","author":"S Sardiwal","year":"2013","unstructured":"Sardiwal S, Magnusson P, Goldsmith DJ, Lamb EJ (2013) Bone Alkaline Phosphatase in CKD\u2013mineral bone disorder. Am J Kidney Dis 62:810\u2013822","journal-title":"Am J Kidney Dis"},{"key":"1195_CR52","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584\u2013592","journal-title":"N Engl J Med"},{"issue":"23","key":"1195_CR53","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W et al (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23):2432\u20132439","journal-title":"JAMA"},{"issue":"10","key":"1195_CR54","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","volume":"22","author":"J Kendrick","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS et al (2011) FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22(10):1913\u20131922","journal-title":"J Am Soc Nephrol"},{"key":"1195_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0272-6386(12)70118-X","volume":"19","author":"BA Julian","year":"1992","unstructured":"Julian BA, Quarles LD, Niemann KM et al (1992) Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 19:99\u2013120","journal-title":"Am J Kidney Dis"},{"key":"1195_CR56","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/TP.0b013e3182855565","volume":"95","author":"E Gonzalez","year":"2013","unstructured":"Gonzalez E, Rojas-Rivera J, Polanco N et al (2013) Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation 95:e49\u2013e52","journal-title":"Transplantation"},{"key":"1195_CR57","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/ajt.12227","volume":"13","author":"H Amer","year":"2013","unstructured":"Amer H, Griffin MD, Stegall MD et al (2013) Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 13:1576\u20131585","journal-title":"Am J Transplant"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1195-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-015-1195-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1195-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T06:54:25Z","timestamp":1654066465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-015-1195-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s11255-015-1195-6","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}